{
    "organizations": [],
    "uuid": "8a9a1f7059087f37471c21cdab397214418a4496",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-saniona-reports-results-from-tesom/brief-saniona-reports-results-from-tesomet-phase-2a-interim-study-in-prader-willi-syndrome-idUSFWN1P3022",
    "ord_in_thread": 0,
    "title": "BRIEF-Saniona Reports Results From Tesomet Phase 2A Interim Study In Prader-Willi Syndrome",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - SANIONA AB:\n* REG-SANIONA AB: SANIONA REPORTS TOP LINE RESULTS FROM THE TESOMET PHASE 2A INTERIM STUDY IN PRADER-WILLI SYNDROME\n* ‍PLASMA CONCENTRATIONS OF TESOFENSINE WERE FOUND TO BE 2 TO 4 TIMES HIGHER IN THIS STUDY COMPARED TO PREVIOUS STUDIES​\n* ‍SAYS RESULTS MUST BE INTERPRETED WITH CAUTION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-08T15:13:00.000+02:00",
    "crawled": "2018-01-09T17:16:38.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "saniona",
        "ab",
        "ab",
        "saniona",
        "report",
        "top",
        "line",
        "result",
        "tesomet",
        "phase",
        "2a",
        "interim",
        "study",
        "syndrome",
        "concentration",
        "tesofensine",
        "found",
        "time",
        "higher",
        "study",
        "compared",
        "previous",
        "result",
        "must",
        "interpreted",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}